Research Use Only (RUO). This guide covers supplier qualification, analytical review, and laboratory handling of Semax raw material. It does not provide dosing, administration, or therapeutic guidance.
Quick answer: what should buyers verify before ordering bulk Semax?
Confirm that the quotation describes Semax with the full sequence Met-Glu-His-Phe-Pro-Gly-Pro and the intended terminal groups, rather than a vague “Semax family” material. The expected average molecular mass for the commonly referenced free-base structure is approximately 813.93 g/mol. Require batch-specific HPLC and mass-spectrometry data, but also define limits for oxidized Semax, deletion sequences, peptide content, water, counter-ion, and residual solvents. Finally, establish how the third-party sample is taken from the saleable batch.
The last point is regularly missed. A laboratory report proves the properties of the submitted sample. It does not prove that the sample represents every bag or vial in a commercial lot. For a scale purchase, analytical quality and sampling quality have to be evaluated together.
Do not confuse Semax with modified analogues
Semax, N-acetyl Semax, and amidated or otherwise modified analogues are not interchangeable analytical identities. Their names can appear close in supplier catalogs, yet terminal modification changes molecular mass, chromatographic retention, solubility, and potentially the impurity profile. A certificate headed only “Semax” is therefore insufficient if the sequence and termini are absent.
The purchase specification should state the full amino-acid sequence, one-letter sequence, terminal groups, stereochemistry, theoretical average and monoisotopic masses, counter-ion, and material basis. The product label, packing list, COA, chromatogram, and mass-spectrum file should all use the same identity. If one document states TFA salt and another states acetate without a controlled conversion record, stop the release review.
Mass spectrometry should show the calculated and observed ions with charge assignments. For a molecule near 814 Da, singly and multiply charged species or common adducts may be visible depending on the ionization conditions. The report must explain which ion supports identity and the allowed mass error. A screenshot containing an unlabeled peak is not a defensible identity result.
Semax has an oxidation risk that a headline purity number can hide
The N-terminal methionine residue is oxidation-sensitive. Methionine sulfoxide formation adds about 16 Da and may produce a related chromatographic peak. Exposure to peroxide residues, oxygen, light, unsuitable excipients, or prolonged aqueous storage can increase this impurity. The supplier should demonstrate that the release method resolves the main peak from oxidized material, not merely report total peak area.
Ask for a forced-oxidation chromatogram during qualification. A small controlled peroxide challenge or another justified stress condition can establish where the oxidized species elutes and whether it is separated. This experiment does not need to appear on every batch COA, but the validated method should be traceable to it. Without specificity evidence, “99% by HPLC” may reflect co-elution rather than a clean impurity profile.
The 2026 FDA review material for Semax noted limited information on potential impurities and aggregation and highlighted impurity controls as an important COA attribute. It also reproduced supplier information describing a white lyophilized solid, TFA counter-ion, a molecular weight of 813.93, and a tested batch with 96.1% HPLC purity. The practical lesson is not that one value applies to all Semax. It is that form, impurity limits, and method evidence need to be explicit for each batch.
How to review the HPLC package
A useful HPLC report includes column chemistry, dimensions, mobile phases, gradient table, flow, temperature, detection wavelength, injection amount, runtime, system suitability, complete chromatogram, and integration table. Semax contains phenylalanine and peptide bonds, so UV detection can be performed at peptide-bond wavelengths, while method sensitivity and selectivity still depend heavily on conditions.
Look beyond the area percentage. Check peak width, shoulders, fronting or tailing, baseline behavior, unresolved clusters, blank interference, and peaks excluded from integration. Verify that the runtime is long enough to elute hydrophobic and strongly retained by-products. Two suppliers can both claim 99%, yet one may use a method that resolves oxidation and deletion sequences while the other compresses them into the main peak.
For incoming verification, match the supplier method when comparability is the objective, then consider an orthogonal method for periodic surveillance. LC-MS can link impurity peaks to plausible mass changes. High-resolution MS is particularly useful during investigation, although it does not replace a validated quantitative method.
Purity is not the same as milligrams of peptide
HPLC area purity answers what fraction of detected chromatographic area belongs to the principal peak under one method. It does not establish the amount of Semax in a weighed portion. Water, TFA or acetate, residual solvent, and inorganic residue can all contribute to gross mass.
For bulk powder or private-label filling, define net peptide content separately. Amino acid analysis or a qualified quantitative method can support content assignment. Pair it with Karl Fischer water and counter-ion testing. State whether vial claims are based on total lyophilized material, Semax free-peptide equivalent, or a named salt. This prevents an apparently high-purity lot from producing underfilled finished units.
Residual solvent limits should reflect the manufacturing and purification process. If the supplier changes resin, cleavage chemistry, purification modifier, counter-ion exchange, or drying cycle, require notification. Those changes may affect impurity patterns and apparent content even when the sequence is unchanged.
Sampling and batch traceability
For a bulk Semax peptide supplier, request a batch map showing synthesis, purification, pooling, drying, bulk packaging, and any later vial filling. The lot number on the independent report should match the lot on the shipped container. If a batch was blended, re-dried, or repacked after testing, the supplier should document why the original result remains representative.
Pre-shipment samples are helpful but vulnerable to selection bias. Define whether the sample will be randomly drawn from finished bulk, whether several containers will contribute, and who will seal it. At receipt, photograph seals and labels, record temperature evidence where agreed, reconcile weight, and quarantine material until critical tests pass. For filled-vial orders, sample early, middle, and late filling positions to detect fill drift or concentration non-uniformity.
Storage claims need actual stability evidence
Lyophilized Semax is commonly specified for cold, dry, light-protected storage, but a temperature statement alone is not a shelf-life study. Request the container-closure description, residual-moisture target, stability protocol, time points, and stability-indicating assay results. Ask how excursions during international transit are assessed.
After solution preparation, oxidation and adsorption to surfaces become more relevant. Laboratories should validate solvent, concentration, container, light protection, temperature, and maximum hold time for their own analytical workflow. Repeated freeze-thaw cycles can add variability; aliquoting may reduce that risk when compatible with the validated protocol.
Seven questions for the supplier
- What exact Semax sequence, termini, counter-ion, and molecular mass are supplied?
- Does the HPLC method separate methionine-oxidized Semax and major deletion sequences?
- Can you provide raw chromatograms, integration tables, and labeled MS spectra?
- Is the quoted quantity gross powder or net Semax peptide content?
- How are water, counter-ion, residual solvents, and container uniformity controlled?
- Who selected the third-party sample, and from which production stage?
- Will the approval sample and commercial order follow the same specification and change-control rules?
A technically strong quotation answers these questions before price negotiation. When contacting a supplier, provide the required form, batch size, packaging configuration, analytical limits, destination, and documentation needs. That allows the technical team to identify oxidation-control or salt-form differences before a purchase order is issued.